Novel Polypharmacological Treatment Options for Obesity and Diabetes
Dr. Timo Müller, Director (acting), Institute for Diabetes and Obesity, Helmholtz Center, Munich, Germany presents an introduction to the physiology and pathophysiology of GIP and GLP-1 in metabolic diseases and treatment strategies based on (poly-)agonists of incretins and related hormones.
Watch the webinar Novel Polypharmacological Treatment Options for Obesity and Diabetes
